論文・技術情報追加のお知らせ

1. Cerebral venous sinus thrombosis risk across various oral contraceptives: a disproportionality analysis of the FDA adverse event reporting system.

経口避妊薬の成分別脳静脈洞血栓症リスクをFAERSで解析。

対象DB：FAERS

2. Association between ranitidine use and thyroid cancer based on FAERS and VigiAccess databases.

ラニチジン使用と甲状腺がんリスクの関連をFAERS等で解析。

対象DB：FAERS

3. Exploring risk signals of association between drugs and suicide: a retrospective investigation from 2004 to 2024.

薬剤と自殺の関連リスクシグナルを副作用DBから後方視的解析。

対象DB：FAERS

4. Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab: A FAERS Observational Study.

ニルセビマブとパリビズマブの副作用報告をFAERSで比較解析。

対象DB：FAERS

5. Factors associated with serious adverse event following immunization: a real-world analysis of the vaccine adverse event reporting system 2025.

ワクチン接種後の重篤な有害事象に関連する因子のリアルワールド解析。

対象DB：FAERS,VAERS

6. A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications.

転移性・切除不能胃腸間質腫瘍（GIST）治療薬の副作用解析。

対象DB：FAERS

7. Atypical Shoulder Pain and Dysfunction After Vaccinations Reported to the Vaccine Adverse Event Reporting System (VAERS) January 1, 2018, Through October 31, 2022.

ワクチン接種後の非典型的な肩の痛みと機能障害をVAERSで調査。

対象DB：FAERS,VAERS

8. A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis-Related Safety Signals.

大麻関連の副作用シグナル検出におけるFAERSの有用性評価。

対象DB：CVAR,FAERS

9. Denosumab safety in men with osteoporosis: a disproportionality analysis of the FAERS database.

男性骨粗鬆症患者におけるデノスマブの安全性をFAERSで解析。

対象DB：FAERS

10. Pharmacovigilance signal detection of central nervous system demyelinating diseases following human papillomavirus vaccination: data mining and signal analysis based on the VAERS database.

HPVワクチン接種後の中枢神経系脱髄疾患シグナルの薬物監視。

対象DB：FAERS,VAERS

11. Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis.

ダサチニブ関連乳び胸のスコープ評価と薬物監視解析。

対象DB：FAERS

12. Postmarketing Safety Concerns With FDA Black Box Warning Monoclonal Antibodies: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database.

黒枠警告付きモノクローナル抗体の市販後安全性をFAERSで解析。

対象DB：FAERS

13. Seizures Risk Related to Atypical Antipsychotics: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS).

非定型抗精神病薬による痙攣リスクをFAERSで不均衡解析。

対象DB：FAERS

14. Real world pharmacovigilance assessment of drug related perinatal depression risks.

薬剤性周産期うつ病リスクのリアルワールドでの薬物監視評価。

対象DB：FAERS

15. Osimertinib-induced interstitial lung disease insights from faers signal detection and network toxicology analysis.

オシメルチニブ誘発性間質性肺疾患のシグナルと毒性機序解析。

対象DB：FAERS

16. A real-world pharmacovigilance study of dacomitinib based on FDA adverse event reporting system (FAERS) database.

ダコミチニブの安全性をFAERSデータに基づきリアルワールド解析。

対象DB：FAERS

17. Holospinal epidural abscess: a review of clinical characteristics, outcomes and prognostic factors.

全脊椎硬膜外膿瘍の臨床的特徴、転帰および予後因子のレビュー。

対象DB：JADER

18. Early cerebral venous drainage associated with a brain tumor: a correlation of digital subtraction angiography and MRI. Illustrative case.

脳腫瘍に伴う早期脳静脈還流とDSAおよびMRI所見の相関。

対象DB：JADER

19. Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance.

偽造セマグルチドの特性をEudraVigilanceデータから解析。

対象DB：EudraVigilance

20. Epidemiology and clinical characteristics of hospitalized patients with echinococcosis in Japan: A nationwide administrative database study.

日本におけるエキノコックス症入院患者の疫学と臨床的特徴。

対象DB：DPC

21. Economic Burden of Cachexia in Japanese Lung Cancer Patients: A Retrospective Claims Database Analysis.

日本のがん患者における悪液質の経済的負担をレセプト解析。

対象DB：JMDC

22. Sequential Use of Systemic Therapy With Locoregional Therapy for Hepatocellular Carcinoma in Japan: Analyses of Real-World Data Based on a Health Claims Database.

日本の肝細胞がんに対する全身療法と局所療法の順序と転帰。

対象DB：MDV

23. Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study.

COPD患者における3剤配合吸入剤2種の有効性と安全性の比較。

対象DB：CPRD

24. Body Mass Index and All-Cause, Cancer, and Cardiovascular Mortality in Adults Aged 16-50 Years With and Without Type 2 Diabetes: An Analysis of Primary Care Records in England.

若年・中年2型糖尿病患者のBMIと全死亡・死因別死亡の関連。

対象DB：CPRD

25. Antibiotic prescribing in people with and without diabetes: a population-based matched cohort study.

糖尿病の有無による抗菌薬処方傾向を住民ベースのコホートで調査。

対象DB：CPRD

26. Imputation Free Deep Survival Prediction with Conditional Variational Autoencoders.

条件付き変分オートエンコーダを用いた補完不要の生存予測。

対象DB：CPRD

27. Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data.

SGLT2阻害薬使用中の2型糖尿病患者におけるGLP-1薬の腎転帰。

対象DB：CPRD

28. Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism.

パーキンソン症候群患者の脆弱性骨折後の骨粗鬆症治療予測因子。

対象DB：CPRD

29. Clinical burden and healthcare resource use of congenital thrombotic thrombocytopenic purpura in England: A linked primary and secondary care data analysis.

イングランドにおける先天性血栓性血小板減少性紫斑病の臨床的負担。

対象DB：CPRD

30. Increased fracture risk associated with iron-deficiency anemia: a population-based propensity score matched cohort study.

鉄欠乏性貧血に伴う骨折リスク増加を住民ベースのPS分析で評価。

対象DB：THIN

31. Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data.

日本のレセプトデータを用いた緑内障配合点眼液の治療継続率解析。

対象DB：DeSC

32. Real-world perioperative systemic treatment patterns and outcomes in patients with urothelial carcinoma undergoing radical surgery.

尿路上皮がん患者における周術期全身療法の治療パターンと転帰。

対象DB：DeSC

33. Relationship of Depression With Incident Cardiovascular Disease in Individuals With Chronic Kidney Disease.

慢性腎臓病患者におけるうつ病と心血管疾患発症リスクの関連。

対象DB：DeSC